CION Ameerpet
The price of a genetic test is set almost entirely by how much DNA the laboratory reads — and the widest test is not always the right one. A focused test for a change already identified in your family costs a fraction of a full panel, and for a relative it is also the more useful test. The expensive mistake is rarely paying too much per gene. It is buying the wrong test, or buying the right test for the wrong person in the family.
If you have searched brca test cost india and found figures that differ several times over, the laboratories are not disagreeing with each other. They are quoting different tests. A test for one specific change already known in your family, a full reading of both BRCA genes, and a panel covering twenty or more hereditary cancer genes are three separate products, and the gap between them is the gap in your search results.
What a laboratory sells is analysis. In a single-site test it checks one position. In a full BRCA1 and BRCA2 analysis it reads both genes from end to end, and a complete version adds a second technique to find whole sections of a gene that have been deleted or duplicated, which sequencing alone can miss. In a multi-gene panel it does all of that across a longer list of genes, then has to interpret every uncertain finding that comes out of them. More genes read means more to classify, more to report and more to explain.
We publish an indicative band rather than a headline price, because a headline price for a test nobody has yet chosen is meaningless. Across Indian laboratories, BRCA testing usually falls somewhere between ₹10,000 and ₹45,000, with a single-site family test at the bottom of that range, full BRCA1 and BRCA2 analysis in the middle, and a broad hereditary cancer panel at the top. Your own figure depends on the test chosen and the laboratory used, and it is confirmed with you before any sample is taken.
A single-site test checks one known change. Full analysis reads both BRCA genes end to end. A panel adds a longer list of hereditary cancer genes. Three tests, three prices, one confusing set of search results.
Roughly ₹10,000 to ₹45,000 across Indian laboratories, depending on scope and on the lab. Indicative only — the point of the consultation is to work out where in that range you actually belong.
A quoted brca testing price means nothing until you know which genes are read, by which methods, and whether counselling and reanalysis sit inside the figure or outside it.
Genetic testing after an ovarian cancer diagnosis is not an optional extra bought out of curiosity about the family. Guidelines recommend that every woman diagnosed with epithelial ovarian, fallopian tube or primary peritoneal cancer is offered germline testing, regardless of her age and regardless of family history — because as many as one in five of these cancers is associated with an inherited variant, and because the result changes two things at once. It determines which maintenance therapies may be open to her, and it tells her blood relatives whether they carry a risk they can act on. That is why the cost question deserves answering properly rather than deferring: this test sits inside treatment planning, not beside it. Source: NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic; Society of Gynecologic Oncology clinical practice statement on genetic testing in ovarian cancer.
Searches for genetic testing cost ovarian cancer return one number for what are really five different tests. This is what each does, and roughly where it sits on price.
| Test | What the laboratory actually does | Where it sits on price |
|---|---|---|
| Single-site (known familial variant) test | Looks only for the one change already confirmed in a relative. Fast, focused, and definitive for that variant. | Lowest. Only possible once an affected relative has been tested first. |
| Full BRCA1 and BRCA2 analysis | Reads both genes end to end, and adds large-rearrangement analysis to detect whole deleted or duplicated sections that sequencing alone misses. | Middle of the band. Ask specifically whether large-rearrangement analysis is included. |
| Multi-gene hereditary cancer panel | Reads BRCA1 and BRCA2 alongside other genes linked to ovarian, breast, bowel and endometrial cancer risk, including the Lynch syndrome genes. | Upper end. More genes also means more uncertain findings to interpret. |
| Tumour (somatic) testing | Run on tissue removed at surgery or biopsy rather than on blood. Answers what the cancer carries, which is not always what you inherited. | Priced separately, and it tells your relatives nothing about their own risk. |
| HRD testing on tumour tissue | Looks beyond BRCA for the wider pattern of damage that marks a tumour as homologous-recombination deficient. Used when planning maintenance treatment. | Usually the most expensive, and often sent to a specialised laboratory. |
*Germline testing uses blood or saliva and answers what you inherited. Tumour testing uses tissue and answers what the cancer carries. They are different tests at different prices, and one does not replace the other — what each result changes is set out in ovarian cancer treatment in Hyderabad, and the mechanics of the test itself in how BRCA testing works.
None of these means a laboratory is being dishonest. Most are simply not in the brochure, and each is a reason to ask one more question before you pay.
Ask which genes are analysed and by which method. A cheap test that reads only part of a gene is not cheaper — it is incomplete, and you will pay again.
Sequencing can miss whole sections of a gene that are deleted or duplicated. Ask whether deletion and duplication analysis is inside the quoted figure.
A result nobody explains is worth very little. Ask whether counselling before and after is included. At CION it sits inside the free consultation.
Consumer DNA kits check a small fixed set of variants and can miss the change your family carries. A reassuring result from one is not a clear BRCA result.
If nobody in the family has been tested yet, the informative sample is from the relative who has cancer. Testing you first can cost more and still answer nothing.
Ask what happens if a variant of uncertain significance is reported: whether reanalysis is free, and who contacts you if the classification later changes.
If a laboratory or hospital will not put the inclusions in writing, that is itself an answer. You are also entitled to take the quote elsewhere first — a genetic counselling appointment is where the question of which test you need actually gets settled, and at CION it costs nothing.
A 45-minute consultation, your family history drawn out properly, and a clear answer on which test would change anything — for you or for your relatives — before a sample is taken or a rupee is spent.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
The first consultation is free and no referral is needed. If testing will not change anything for you or your family, we will say so plainly, and that conversation costs you nothing.
In this order. Families who reverse the first two steps routinely pay for a broad panel that answers a question nobody needed to ask.
This single decision moves the total cost more than any price list does. If a relative has ovarian or breast cancer, the informative test is on her, because a normal result in a healthy relative means very little while the family variant is still unknown. Once a variant is identified, everyone else needs only the focused single-site test, at a fraction of the price. Testing the worried well first is the commonest and most expensive sequence we see.
A woman diagnosed with epithelial ovarian cancer needs full germline analysis, and may need tumour or HRD testing as well if maintenance therapy is being planned. A relative of a known carrier needs a single-site test and nothing more. A family history spread across breast, bowel and endometrial cancer is where a wider panel earns its price. Outside those situations a panel buys uncertainty rather than safety.
Ask for one list: which genes, by which methods, whether deletion and duplication analysis is included, the sample type, the turnaround (usually about two to four weeks in India), whether the report includes interpretation and counselling, what reanalysis costs if a variant is uncertain, and what relatives will be charged for single-site testing later.
Some private insurers reimburse genetic testing where there is a clear medical indication, and a test in a woman already diagnosed is far more likely to qualify than predictive testing in a healthy relative. Ask your insurer in writing rather than over a call centre line. Aarogyasri in Telangana, NTR Vaidya Seva in Andhra Pradesh and PM-JAY pay against defined packages at empanelled hospitals with pre-authorisation raised in advance, so ask the treating hospital whether your test maps to a listed package rather than assuming that it does.
Ask what relatives will pay for the focused test, and how long the laboratory keeps the family variant on file. Families often test one person, then return a year later to find the reduced rate has lapsed or the report has to be re-issued. Settling it in one conversation costs nothing; discovering it later does. What the appointment itself involves is described in genetic counselling for ovarian cancer.
*BRCA and HRD testing, and the genetic counselling around them, are delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh. Any risk-reducing gynaecological surgery that a result leads to is coordinated with specialist gynaecologic-oncology partner centres, where it is performed and billed separately.
The cost question usually arrives with a second question hidden inside it: is this test worth doing at all? The two get answered in the wrong order almost every time. Families ring three laboratories, compare three numbers, and only afterwards discover that the person who should have been tested was somebody else, or that the panel they paid for has reported something nobody can act on.
Your first consultation at CION is free and runs to about 45 minutes. In that time a specialist draws your family history out properly — who was diagnosed, with what, and at what age, on both sides — and tells you which test, if any, would change a decision. Sometimes the answer is that no test is needed yet. Sometimes it is that the right person to test lives in another city. Neither answer costs you anything, and both are cheaper than a panel bought on price alone.
Where testing is warranted, genetic counselling and BRCA and HRD testing are delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh, alongside chemotherapy, maintenance therapy, nutrition support and follow-up. You are given the exact figure before a sample is taken, and told plainly what the report will and will not be able to say. Where a result leads to risk-reducing surgery, that surgery is coordinated with specialist gynaecologic-oncology partner centres, where it is performed and billed — we would rather say so now than leave you to find it on an invoice.
Free, unhurried and with a specialist. Long enough to take the family history that decides which test is worth paying for, rather than glance at a pedigree.
Which test you need is settled in counselling, not by a price list. The counselling before and after testing is part of the consultation, not a separate line on a bill.
Genetic counselling, BRCA and HRD testing, chemotherapy and maintenance therapy are ours. Surgery is coordinated with partner centres and billed there. You should know which is which.
Decisions for healing, not billing. If a broader panel will not change your treatment or your family's screening, we will tell you so instead of selling it to you.
Across Indian laboratories it usually falls somewhere between roughly ₹10,000 and ₹45,000, and where you land in that band is decided by the test rather than by the city. A focused single-site test, looking only for a change already confirmed in your family, sits at the bottom. Full BRCA1 and BRCA2 analysis, reading both genes end to end with large-rearrangement analysis added, sits in the middle. A multi-gene hereditary cancer panel sits at the top, because more genes mean more analysis and more uncertain findings to interpret. Treat any figure quoted before someone has taken your family history as indicative only. At CION the exact price is confirmed before a sample is taken.
Because the laboratory is reading and classifying far more DNA. A panel covers BRCA1 and BRCA2 alongside other genes linked to ovarian, breast, bowel and endometrial cancer risk, and every one of them can throw up a finding that has to be interpreted, reported and explained. The hidden cost is not the sequencing but the uncertainty: the more genes you read, the more likely it is that a variant of uncertain significance appears, and that is a result nobody can act on until it is reclassified. A panel earns its price when the family history spans several cancer types. When the question is narrow, a narrow test answers it better and for less.
Sometimes, and it has to be confirmed rather than assumed. Some private insurers reimburse genetic testing where there is a clear medical indication, and a test in a woman already diagnosed with ovarian cancer, where the result guides her treatment, is far more likely to qualify than predictive testing in a healthy relative. Ask your insurer in writing before the sample is taken. Aarogyasri in Telangana, NTR Vaidya Seva in Andhra Pradesh and PM-JAY nationally pay against defined packages at empanelled hospitals, and normally require pre-authorisation before treatment begins, so ask the treating hospital whether your specific test maps to a listed package. Our team helps check eligibility and raise pre-authorisation in advance.
Yes, and this is the largest saving available to any family. Once a pathogenic variant has been identified in one person, relatives need only a single-site test that looks for that exact change, which is the least expensive and fastest genetic test there is. This is why the order of testing matters so much. If nobody in the family has been tested, the informative sample is from the relative who has cancer, because a normal result in a healthy person means very little while the family variant remains unknown. Ask about the cascade rate at the same time as your own quote, and ask how long the laboratory keeps the family variant on file.
No, and treating it as one is genuinely risky. Consumer ancestry kits that report on BRCA check a small, fixed set of variants, most often the few that are common in specific populations. They do not read the genes end to end and they do not look for large deleted or duplicated sections, so they can easily miss the change a family carries. A reassuring line in an ancestry report is not a clear BRCA result, and no clinical decision, including surgery or screening, should rest on one. If the question matters enough to ask, it matters enough to answer with a diagnostic-grade test reported alongside counselling.
The first consultation is free and runs to about 45 minutes, and no referral is needed. Genetic counselling and BRCA and HRD testing are delivered in-house at CION, across more than 35 centres in Telangana and Andhra Pradesh, alongside platinum-based chemotherapy, maintenance therapy, nutrition support and follow-up. Which test you need is decided in counselling, and the exact price is confirmed before any sample is taken. Where a result leads to risk-reducing gynaecological surgery, that surgery is coordinated with specialist gynaecologic-oncology partner centres, where it is performed and billed, and we say so upfront. Bring your family history, and any pathology report or quote you already have.